703-1086

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
703 (USA) · Dr. Okafor
consented 2012-09-02

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Mild APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-09-13 (study day 12.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-09-13 (study day 12.0); relationship: PROBABLE

severe assessed

Severe APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-09-13 (study day 12.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE IRRITATION — outcome: RECOVERED/RESOLVED; onset 2012-09-13 (study day 12.0); relationship: PROBABLE

mild assessed

Mild CHILLS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-10-09 (study day 38.0); relationship: POSSIBLE

mild assessed

Mild CHILLS — outcome: RECOVERED/RESOLVED; onset 2012-10-09 (study day 38.0); relationship: POSSIBLE

Data queries

No data queries.